Ventricular high-rate episodes predict increased mortality in heart failure patients treated with cardiac resynchronization therapy.
(2015) In Scandinavian Cardiovascular Journal 49(1). p.20-26- Abstract
- Abstract Objectives. Cardiac Resynchronization Therapy (CRT) for heart-failure patients has a well-documented positive effect, but the overall mortality in this group remains high. This study aimed to explore whether additional information from the device post-implant (occurrence of ventricular high-rate episodes), could add prognostic value for patients on CRT-pacemaker (CRT-P) treatment. Design. Clinical data and device-interrogation data were retrospectively gathered from the medical records of 220 patients treated with CRT-P. Ventricular high-rate (VHR) episodes were defined as a ventricular rate ≥ 180 beats per minute. The primary outcome was 5-year mortality. Results. During follow-up, 132 patients (60%) died or underwent heart... (More)
- Abstract Objectives. Cardiac Resynchronization Therapy (CRT) for heart-failure patients has a well-documented positive effect, but the overall mortality in this group remains high. This study aimed to explore whether additional information from the device post-implant (occurrence of ventricular high-rate episodes), could add prognostic value for patients on CRT-pacemaker (CRT-P) treatment. Design. Clinical data and device-interrogation data were retrospectively gathered from the medical records of 220 patients treated with CRT-P. Ventricular high-rate (VHR) episodes were defined as a ventricular rate ≥ 180 beats per minute. The primary outcome was 5-year mortality. Results. During follow-up, 132 patients (60%) died or underwent heart transplant. Overall, the 5-year mortality rate was 52%; 77% for patients with VHR during the first year of follow-up and 48% for patients without VHR during the first year of follow-up (p = 0.001). In a multivariate model, the occurrence of VHR episodes was an independent predictor of 5-year mortality (HR 9.96, p = 0.022). The most common cause of death was heart failure, and death from arrhythmia did not differ between groups (p = 0.065). Conclusions. In heart-failure patients with CRT-P therapy, occurrence of VHR episodes within the first year post-implant was an independent predictor of higher 5-year mortality and inferior long-term survival, but not of death from malignant arrhythmia. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5145284
- author
- Jacobsson, Jonatan LU ; Reitan, Christian LU ; Platonov, Pyotr LU and Borgquist, Rasmus LU
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Scandinavian Cardiovascular Journal
- volume
- 49
- issue
- 1
- pages
- 20 - 26
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:25658030
- wos:000350104900004
- scopus:84923351020
- pmid:25658030
- ISSN
- 1651-2006
- DOI
- 10.3109/14017431.2015.1006245
- language
- English
- LU publication?
- yes
- id
- 43ffb65a-2813-4b71-aa16-6a22b5ac0fe3 (old id 5145284)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25658030?dopt=Abstract
- date added to LUP
- 2016-04-01 10:20:35
- date last changed
- 2022-04-12 05:21:12
@article{43ffb65a-2813-4b71-aa16-6a22b5ac0fe3, abstract = {{Abstract Objectives. Cardiac Resynchronization Therapy (CRT) for heart-failure patients has a well-documented positive effect, but the overall mortality in this group remains high. This study aimed to explore whether additional information from the device post-implant (occurrence of ventricular high-rate episodes), could add prognostic value for patients on CRT-pacemaker (CRT-P) treatment. Design. Clinical data and device-interrogation data were retrospectively gathered from the medical records of 220 patients treated with CRT-P. Ventricular high-rate (VHR) episodes were defined as a ventricular rate ≥ 180 beats per minute. The primary outcome was 5-year mortality. Results. During follow-up, 132 patients (60%) died or underwent heart transplant. Overall, the 5-year mortality rate was 52%; 77% for patients with VHR during the first year of follow-up and 48% for patients without VHR during the first year of follow-up (p = 0.001). In a multivariate model, the occurrence of VHR episodes was an independent predictor of 5-year mortality (HR 9.96, p = 0.022). The most common cause of death was heart failure, and death from arrhythmia did not differ between groups (p = 0.065). Conclusions. In heart-failure patients with CRT-P therapy, occurrence of VHR episodes within the first year post-implant was an independent predictor of higher 5-year mortality and inferior long-term survival, but not of death from malignant arrhythmia.}}, author = {{Jacobsson, Jonatan and Reitan, Christian and Platonov, Pyotr and Borgquist, Rasmus}}, issn = {{1651-2006}}, language = {{eng}}, number = {{1}}, pages = {{20--26}}, publisher = {{Taylor & Francis}}, series = {{Scandinavian Cardiovascular Journal}}, title = {{Ventricular high-rate episodes predict increased mortality in heart failure patients treated with cardiac resynchronization therapy.}}, url = {{http://dx.doi.org/10.3109/14017431.2015.1006245}}, doi = {{10.3109/14017431.2015.1006245}}, volume = {{49}}, year = {{2015}}, }